Morning Read: Bristol-Myers Squibb will acquire immunotherapy group Promedior for $1.25B
Bristol-Myers Squibb has paid for the right to acquire US clinical stage immunotherapy group Promedior in a deal valued at up to $1.25 billion, securing access to the firm’s fibrotic disease candidates.